Article Text


S47 Effect of macitentan on haemodynamics in patients with pulmonary arterial hypertension: results from the long-term, randomised, placebo-controlled SERAPHIN trial
  1. G Coghlan1,
  2. A Torbicki2,
  3. N Galiè3,
  4. LJ Rubin4,
  5. L Perchenet5,
  6. G Simonneau6
  1. 1Royal Free Hospital, London, United Kingdom
  2. 2Department of Pulmonary Circulation and Thromboembolic Diseases, Center of Postgraduate Medical Education, ECZ-Otwock, Poland
  3. 3University of Bologna, Bologna, Italy
  4. 4Division of Pulmonary & Critical Care Medicine, University of California, San Diego, USA
  5. 5Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
  6. 6Service de Pneumologie, Hôpital Universitaire de Bicêtre, Le Kremlin Bicêtre, France


Introduction and objectives Macitentan, a novel dual endothelin receptor antagonist (ERA), significantly reduced morbidity and mortality in pulmonary arterial hypertension (PAH) patients in the SERAPHIN trial (NCT00660179), the first event-driven outcomes trial in PAH. A substudy in SERAPHIN investigated the effect of macitentan on patients' cardiac haemodynamics.

Methods 742 PAH patients were randomised to placebo, macitentan 3 mg, or macitentan 10 mg once-daily. Stable background PAH therapy, except injectable prostanoids and other ERAs, were allowed. At selected centres, patients underwent right heart catheterisation at randomisation and Month 6. Changes from baseline to Month 6 for mean right atrial pressure (mRAP), mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), cardiac index (CI) and mixed venous oxygen saturation (SvO2) were calculated for all patients and stratified in an exploratory analysis for background PAH therapy and baseline WHO functional class I/II vs III/IV. Median treatment effects (95% CL) between placebo and macitentan are reported.

Results 187 patients participated in the substudy (51% were treatment-naïve and 56% in WHO FC III/IV). Baseline median values for all patients on placebo (n = 68), macitentan 3 mg (n = 62) and 10 mg (n = 57) were: mRAP 7.0, 8.0, 7.0 mmHg; mPAP 52.0, 54.0, 52.3 mmHg; PVR 800, 785, 789 dyn·sec/cm5; CI 2.49, 2.23, 2.47 L/min/m2; and SvO2 66.0, 64.5, 66.5%, respectively. Overall, haemodynamic parameters improved at Month 6 with macitentan and worsened with placebo. Beneficial treatment effects with macitentan were statistically significant (P < 0.05) for PVR and CI for both subgroups, except for PVR in treatment naïve patients treated with macitentan 3mg (Table).

Abstract S47 Table 1.

Median treatment effects on PVR and CI

Conclusions Macitentan significantly improved cardio-pulmonary haemodynamics in PAH patients. Improvements in PVR and CI were consistent irrespective of background PAH therapy and baseline WHO FC.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.